Carnival of Biotechnology

Investing and Clinical Trials

PharmaGossip has an illuminating excerpt from The End of Medicine describing a method to invest in drug companies as they progress through clinical trials.
Ted Love, CEO of Nuvelo Inc., explains how biotechnology companies are frequently able to recover from seemingly disastrous clinical trial failures.
Patents
When manufacturers seeking to sell generic drugs challenge patents [...]

Carnival of Biotechnology

Scientific Advances
The MaRS Blog has a captivating story of Canada’s recent major diabetes discovery. The first discovery, in 1920, elucidated insulin’s central role in diabetes. The most recent discovery, also from the University of Toronto, has found a strong link between diabetes, pain nerves, and inflammation. Researchers were able to prevent and even reverse diabetes [...]

Carnival of Biotechnology

This edition of the Carnival of Biotechnology features a number of posts on distressing industry trends, some enlightening patent discussion, and interesting commentary on issues in commercialization
Industry Trends
Forbes presents Genentech’s Next Act. his dialogue with Genentech’s chief officers acknowledges the longshot Genentech was in its early days and plots the future paths Genentech is pursuing [...]

Carnival of Biotechnology

Lots of interesting developments since the last edition: Pfizer’s high-profile drug failiure, a new law against violent extremists, good news for Merck, and good and bad news for the biotechnology industry as a whole.
News and Trends
The Washington Times has an update on the signing of the Animal Enterprise Terrorism Act. Bolstered by recent bombings [...]

Carnival of Biotechnology

Intellectual Property and Lawsuits

Culture Dish has a post on a DNA sequencing technique patent dispute — Enzo biochem claims that they invented the technique for sequencing DNA, though the patent on it was awarded to some scientists at Caltech nearly 25 years ago.
Pharmablogger presents an inside view of a series of 7,000 complaints filed by [...]

Carnival of Biotechnology

This edition of the Carnival of Biotechnology features some interesting commentary on issues ethics, how to dress for drug ads, progress in biogenerics guidance, and innovation.
Trends
Signals Magazine presents a Financial Snapshot For September 2006
Marketing
The Pharma Marketing Blog gives us some fashion advice in Lipitor’s Jarvik: Fop or Flop?
Ethics
The Patent Baristas give us a double-header: [...]